X
All Data
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2020
Details:
Sanofi is working on two vaccine projects to prevent COVID-19. Of more than 100 vaccine candidates in development, 10 have reached the clinical testing stage so far.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): S-protein COVID-19 antigen
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: GlaxoSmithKline
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 14, 2020
Details:
Sanofi will contribute its S-protein COVID-19 antigen and GSK will contribute its proven pandemic adjuvant technology to the collaboration.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): SARS vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Biomedical Advanced Research and Development Authority
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 18, 2020
Details:
Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi’s well-established recombinant technology platform to expedite a potential COVID-19 vaccine.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Translate Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 27, 2020
Details:
Translate Bio will use its mRNA platform to discover, design, and manufacture a range of SARS-CoV-2 vaccines. Sanofi will provide deep expertise and support from its external research networks.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
